EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study

Jacoline E C Bromberg iD, Samar Issa iD, Bronno van der Holt iD, Matthijs van der Meulen iD, Linda Dirven iD, Monique C Minnema iD, Tatjana Seute iD, Marc Durian, Gavin Cull iD, Marjolein W M van der Poel iD, Wendy B C Stevens iD, Josee M Zijlstra und 8 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad224 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Jacoline E C Bromberg und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Lymphoma. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society, Stichting STOPhersentumoren, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies on the efficacy of rituximab in primary CNS lymphoma (PCNSL) reported conflicting results. Our international randomized phase 3 study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide, and prednisolone (MBVP) in PCNSL was not efficacious in the short term. Here we present long-term results after a median follow-up of 82.3 months.

Methods

One hundred and ninety-nine eligible newly diagnosed, nonimmunocompromised patients with PCNSL aged 18–70 years with WHO performance status 0–3 was randomized between treatment with MBVP chemotherapy with or without rituximab, followed by high-dose cytarabine consolidation in responding patients, and reduced-dose WBRT in patients aged ≤ 60 years. Event-free survival was the primary endpoint. Overall survival rate, neurocognitive functioning (NCF), and health-related quality of life (HRQoL) were additionally assessed, with the IPCG test battery, EORTC QLQ-C30 and QLQ-BN20 questionnaires, respectively.

Results

For event-free survival, the hazard ratio was 0.85, 95% CI 0.61–1.18, P = .33. Overall survival rate at 5 years for MBVP and R-MBVP was 49% (39–59) and 53% (43–63) respectively. In total, 64 patients died in the MBVP arm and 55 in the R-MBVP arm, of which 69% were due to PCNSL. At the group level, all domains of NCF and HRQoL improved to a clinically relevant extent after treatment initiation, and remained stable thereafter up to 60 months of follow-up, except for motor speed which deteriorated between 24 and 60 months. Although fatigue improved initially, high levels persisted in the long term.

Conclusions

Long-term follow-up confirms the lack of added value of rituximab in addition to MBVP and HD-cytarabine for PCNSL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsLymphomaHumansAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineMethotrexatePrednisoloneQuality of LifeRituximabTeniposideMiddle AgedAdolescentYoung AdultAdultAged

Stichwörter der Autor:innen

PCNSLhealth-related quality of lifeneurocognitive functionrituximabtreatment

Substanzen

CarmustineCytarabineMethotrexatePrednisoloneRituximabTeniposide

Autor:innen und Institutionen

  • Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Hematology, Middlemore Hospital, Auckland, New Zealand.
  • HOVON Foundation, Rotterdam, The Netherlands.
  • Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands.
  • Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Jacoline E C Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C Minnema, Tatjana Seute, Gavin Cull, Marjolein W M van der Poel, Wendy B C Stevens, Dieta Brandsma, Marcel Nijland, Kylie D Mason, Aart Beeker, Martine C J Abrahamse-Testroote, Martin J van den Bent, Daphne de Jong, Jeanette K Doorduijn

Förderung

  • Dutch Cancer Society
  • Stichting STOPhersentumoren
  • Roche

Zitieren

APA

Bromberg, J. E. C., Issa, S., van der Holt, B., van der Meulen, M., Dirven, L., Minnema, M. C., Seute, T., Durian, M., Cull, G., van der Poel, M. W. M., Stevens, W. B. C., Zijlstra, J. M., Brandsma, D., Nijland, M., Mason, K. D., Beeker, A., Abrahamse-Testroote, M. C. J., van den Bent, M. J., de Jong, D., & Doorduijn, J. K. (2024). Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad224

Vancouver

Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, et al. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad224

BibTeX
@article{Bromberg2024,
  author = {Bromberg, Jacoline E C and Issa, Samar and van der Holt, Bronno and van der Meulen, Matthijs and Dirven, Linda and Minnema, Monique C and Seute, Tatjana and Durian, Marc and Cull, Gavin and van der Poel, Marjolein W M and Stevens, Wendy B C and Zijlstra, Josee M and Brandsma, Dieta and Nijland, Marcel and Mason, Kylie D and Beeker, Aart and Abrahamse-Testroote, Martine C J and van den Bent, Martin J and de Jong, Daphne and Doorduijn, Jeanette K},
  title = {Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad224}
}
Kostenlos starten →